CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Genedrive (GDR) stock up as it seeks UK Covid test approval

By Angela Barnes

12:34, 22 December 2021

Exterior of the London Stock Exchange in the UK
Trials revealed Genedrive’s rapid molecular diagnostic test successfully detected Omicron variant – Photo: Shutterstock

Genedrive saw its stock rise 25.45% on Thursday morning on the London Stock Exchange after the UK company announced that it had filed for approval of its Covid-19 test device.

It highlighted that the Genedrive COV19-ID kit is a rapid molecular diagnostic test that delivers positive results in as little as 7 minutes 30 seconds – and negative results in 17 minutes.

“It utilises reverse-transcription loop mediated isothermal amplification (RT-LAMP) and a proprietary buffer formulation to achieve rapid results without requirement for user viral extraction steps,” the company said in a statement on Wednesday.

“Performed directly from a mid-turbinate nasal swab, the assay targets the ORF1ab and N genes of the SARS-CoV-2 genome, adding robustness against emerging SARS-CoV-2 variants.”

Certification hopes revealed last month

The molecular diagnostics company first announced on 29 November this year that it had submitted an application for CE-IVD certification for its Genedrive COV19-ID Kit – and said the expanded product validation requirements have now been completed.

As a result, the company has filed for approval to sell the product in the UK under the new Coronavirus Test Device Approvals (CTDA) regulations.

NVDA

467.55 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

AMZN

147.02 Price
+0.760% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.14

COIN

134.12 Price
+7.790% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.25

GME

15.36 Price
+5.850% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 0.16

“The expanded clinical validation sample cohort required for CTDA approval was referenced against the Thermo Fisher TaqPath Covid-19 RT-PCR test. In the 264 samples, specificity was 98%, and sensitivity was 98% in samples with viral load 500 copies per millilitre,” it said in a statement.

“This cohort included samples of confirmed Omicron variant, all of which were successfully detected. The sensitivity and specificity of the Genedrive COV19-ID assay on the entire cohort met the current requirements of the UK’s MHRA target product profile for SARS-CoV-2 point-of-care molecular diagnostic tests,” it added.

Company comments on the approval filing

David Budd, CEO of Manchester-based Genedrive (GDR), commented: “CTDA performance data builds on the data already generated for CE certification, and demonstrates that the product meets the expanded UK requirements for point-of-pare COVID-19 molecular tests.

“The next milestone is approval by the Department of Health and Social Care, however, no assured timeline is provided on how long the review under CTDA regulations will take, given a current backlog in its reviews.

“We have confidence in our data and the application is another positive step that allows us now to progress UK focused commercial discussions.”

Read more: UK GDP summer momentum stutters 

Related topics

Rate this article

The difference between trading assets and CFDs
The main difference between CFD trading and trading assets, such as commodities and stocks, is that you don’t own the underlying asset when you trade on a CFD.
You can still benefit if the market moves in your favour, or make a loss if it moves against you. However, with traditional trading you enter a contract to exchange the legal ownership of the individual shares or the commodities for money, and you own this until you sell it again.
CFDs are leveraged products, which means that you only need to deposit a percentage of the full value of the CFD trade in order to open a position. But with traditional trading, you buy the assets for the full amount. In the UK, there is no stamp duty on CFD trading, but there is when you buy stocks, for example.
CFDs attract overnight costs to hold the trades (unless you use 1-1 leverage), which makes them more suited to short-term trading opportunities. Stocks and commodities are more normally bought and held for longer. You might also pay a broker commission or fees when buying and selling assets direct and you’d need somewhere to store them safely.
Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading